Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | FPR1 | P21462 | 1/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30895599 | 0.86 | METAP2 (0.42) | METAP2METAP1NPY5RFPR1ENPP1 | |
| SCHEMBL459827 | 0.75 | METAP2 (0.39) | METAP2METAP1NPY5RFPR1 | |
| SCHEMBL11498402 | 0.75 | METAP2 (0.39) | METAP2METAP1NPY5R | |
| SCHEMBL31064848 | 0.75 | SMN1; SMN2 (0.52) | METAP2METAP1ALDH1A1NPY5RENPP1 | |
| SCHEMBL375955 | 0.75 | SMN1; SMN2 (0.52) | METAP2METAP1ALDH1A1NPY5RENPP1 | |
| SCHEMBL889310 | 0.74 | HSD17B10 (0.39) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL8741745 | 0.74 | METAP2 (0.38) | METAP2METAP1KDM4EFPR1ENPP1 | |
| SCHEMBL798546 | 0.73 | HSD17B10 (0.41) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL890077 | 0.73 | AURKA (0.47) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL9121473 | 0.72 | METAP2 (0.45) | METAP2METAP1NPY5RENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112876474-A | Dimethoxy tetrahydroisoquinoline substituted purine derivative, preparation method thereof and application thereof in antitumor drugs | 林剑雄 | 2021-06-01 | — | — | CN | claimed |
| US-10866241-B2 | Method for the prognosis and treatment of cancer metastasis | INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) | 2020-12-15 | — | — | US | claimed |
| US-12312642-B2 | Method for the diagnosis, prognosis and treatment of breast cancer metastasis | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) (ES) | 2025-05-27 | — | — | US | disclosed |
| US-20250115912-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2025-04-10 | — | — | US | disclosed |
| US-12196758-B2 | Method for the prognosis and treatment of cancer metastasis | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) and INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) | 2025-01-14 | — | — | US | disclosed |
| US-11892453-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | INBIOMOTION S.L. (ES) | 2024-02-06 | — | — | US | disclosed |
| US-11840740-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | INBIOMOTION S.L. (ES) | 2023-12-12 | — | — | US | disclosed |
| US-20230323356-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2023-10-12 | — | — | US | disclosed |
| US-11591599-B2 | Method for the diagnosis, prognosis and treatment of cancer metastasis | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2023-02-28 | — | — | US | disclosed |
| US-11352673-B2 | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) | 2022-06-07 | — | — | US | disclosed |
| US-20220049316-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BREAST CANCER METASTASIS | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) (ES) | 2022-02-17 | — | — | US | disclosed |
| WO-2000044750-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a) | CV THERAPEUTICS, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000043394-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF | ÚSTAV EXPERIMENTÁLNÍ BOTANIKY AV CR (CZ) | 2000-07-27 | — | — | WO | disclosed |
| EP-1021186-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-1021186-A4 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS INC (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000033657-A1 | METHOD TO IDENTIFY REGULATORS OF CDK ACTIVITY | CROPDESIGN N.V. (BE) | 2000-06-15 | — | — | WO | disclosed |
| CN-1231611-A | Puring inhibitors of cylin dependent kinase 2 and I'kappa'beta-'alpha' | CV THERAPEUTIC INC (US) | 1999-10-13 | — | — | CN | disclosed |
| US-5866702-A | Purine inhibitors of cyclin dependent kinase 2 | CV THERAPEUTICS, INCORPORATION (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998005335-A9 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) | — | 1998-05-28 | — | — | WO | disclosed |
| WO-1998005335-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) | CV THERAPEUTICS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230323356-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | MAFG, RHOXF2, MAFK | METAP2 660/4885METAP1 571/4885HSD17B10 3761/4885 |
| US-11892453-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | MAFG, MAFK, ACP3 | METAP2 386/4885METAP1 175/4885HSD17B10 2076/4885 |
| US-12196758-B2 | Method for the prognosis and treatment of cancer metastasis | MAFG, BRCA1, BCOR | METAP2 649/4885METAP1 382/4885HSD17B10 2885/4885 |
| US-11591599-B2 | Method for the diagnosis, prognosis and treatment of cancer metastasis | MAFG, RHOXF2, MAFK | METAP2 660/4885METAP1 571/4885HSD17B10 3761/4885 |
| US-20220049316-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BREAST CANCER METASTASIS | MAFG, MAFK, CRACR2A | METAP2 573/4885METAP1 255/4885HSD17B10 1894/4885 |
| US-11840740-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | MAFG, ACP3, MAFK | METAP2 279/4885METAP1 122/4885HSD17B10 1955/4885 |
| US-20250115912-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | MAFG, RHOXF2, MAFK | METAP2 660/4885METAP1 571/4885HSD17B10 3761/4885 |
| US-11352673-B2 | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | MAFG, MAFK, MYCBP | METAP2 690/4885METAP1 307/4885HSD17B10 3456/4885 |
| US-10866241-B2 | Method for the prognosis and treatment of cancer metastasis | MAFG, BRCA1, BCOR | METAP2 649/4885METAP1 382/4885HSD17B10 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.